Anna Cho
Seoul National University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Anna Cho.
Journal of Neurology, Neurosurgery, and Psychiatry | 2014
Anna Cho; Yukiko K. Hayashi; Kazunari Monma; Yasushi Oya; S. Noguchi; Ikuya Nonaka; Ichizo Nishino
Background GNE myopathy (also called distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy) is an autosomal recessive myopathy characterised by skeletal muscle atrophy and weakness that preferentially involve the distal muscles. It is caused by mutations in the gene encoding a key enzyme in sialic acid biosynthesis, UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE). Methods We analysed the GNE gene in 212 Japanese GNE myopathy patients. A retrospective medical record review was carried out to explore genotype–phenotype correlation. Results Sixty-three different mutations including 25 novel mutations were identified: 50 missense mutations, 2 nonsense mutations, 1 insertion, 4 deletions, 5 intronic mutations and 1 single exon deletion. The most frequent mutation in the Japanese population is c.1714G>C (p.Val572Leu), which accounts for 48.3% of total alleles. Homozygosity for this mutation results in more severe phenotypes with earlier onset and faster progression of the disease. In contrast, the second most common mutation, c.527A>T (p.Asp176Val), seems to be a mild mutation as the onset of the disease is much later in the compound heterozygotes with this mutation and c.1714G>C than the patients homozygous for c.1714G>C. Although the allele frequency is 22.4%, there are only three homozygotes for c.527A>T, raising a possibility that a significant number of c.527A>T homozygotes may not develop an apparent disease. Conclusions Here, we report the mutation profile of the GNE gene in 212 Japanese GNE myopathy patients, which is the largest single-ethnic cohort for this ultra-orphan disease. We confirmed the clinical difference between mutation groups. However, we should note that the statistical summary cannot predict clinical course of every patient.
European Journal of Neurology | 2012
B. Lim; Anna Cho; Hee Hwang; Ki Joong Kim; Yong Seung Hwang; Young-Eun Kim; J. Y. Yun; Beomseok Jeon; Y. H. Lim; Sun Ha Paek; Jong-Hee Chae
Background and Purpose: The purpose of this study was to evaluate the mutation status of PANK2 among Korean patients with pantothenate kinase‐associated neurodegeneration (PKAN) and to document the outcome of pallidal deep brain stimulation (DBS).
Neuromuscular Disorders | 2010
B. Lim; Jong-Won Kim; Anna Cho; Min Jung Kim; Hee Hwang; Ki Joong Kim; Yong Seung Hwang; Woong-Yang Park; Yun-Jung Lim; In One Kim; Jun Su Lee; Jong Hee Chae
This study was aimed to identify Fukutin (FKTN)-related congenital muscular dystrophies (CMD) with defective alpha-dystroglycan glycosylation in Korea and to discuss their genotype-phenotype spectrum focusing on detailed brain magnetic resonance imaging (MRI) findings. FKTN mutations were found in nine of the 12 CMD patients with defective alpha-dystroglycan glycosylation patients (75%). Two patients were homozygous for the Japanese founder retrotransposal insertion mutation. Seven patients were heterozygous for the retrotransposal insertion mutation, five of whom carried a novel intronic mutation that activates a pseudoexon between exons 5 and 6 (c.647+2084G>T). Compared with individuals that were homozygous for the retrotransposal insertion mutation, the seven heterozygotes for the retrotransposal insertion mutation, including five patients with the novel pseudoexon mutation, exhibited a more severe clinical phenotype in terms of motor abilities and more extensive brain MRI abnormalities (i.e., a wider distribution of cortical malformation and pons and cerebellar hypoplasia). FKTN mutations are the most common genetic cause of CMD with defective alpha-dystroglycan glycosylation in Korea. Compound heterozygosity of the retrotransposal insertion and the novel pseudoexon mutation is the most prevalent genotype in Korea and is associated with a more severe clinical and radiological phenotype compared with homozygosity for the retrotransposal insertion mutation.
Muscle & Nerve | 2010
Hunmin Kim; Anna Cho; Byung Chan Lim; Min Jung Kim; Ki Joong Kim; Ichizo Nishino; Yong Seung Hwang; Jong-Hee Chae
Danon disease is caused by deficiency of lysosome‐associated membrane protein‐2 (LAMP‐2). It is characterized clinically by cardiomyopathy, myopathy, and mental retardation in boys. Herein we report a 13‐year‐old female patient with Danon disease who presented with early‐onset skeletal myopathy and cardiomyopathy. She had a de novo novel mutation in the LAMP2 gene, and her muscles showed many autophagic vacuoles with sarcolemmal features and complete absence of LAMP‐2 expression. To the best of our knowledge, this girl is one of the earliest‐onset manifesting carriers of Danon disease with typical muscle pathology. Muscle Nerve, 2010
Journal of Child Neurology | 2012
Anna Cho; Su Jin Kim; Byung Chan Lim; Hee Hwang; June Dong Park; Gi Beom Kim; Dong-Kyu Jin; Jeehun Lee; Ki Joong Kim; Yong Seung Hwang; Jong-Hee Chae
Pompe disease is an autosomal recessive disorder caused by lysosomal acid α-glucosidase deficiency. Infantile-onset Pompe disease presents with cardiomyopathy and hypotonia, leading to premature death. This article describes 7 infantile Pompe disease cases and provides their molecular bases and clinical outcomes after enzyme replacement therapy for the first time in Korea. Molecular genetic analyses revealed the presence of 9 different mutations, including 5 novel mutations (c.2171C>A, c.2774C>T, c.1582_3de12, c.1261_1263Tms, and c.1322_1326+9de114). The most common mutation in these 7 patients was c.1316T>A (28%). Four patients received intravenous recombinant human acid α-glucosidase therapy for 2 years, on average, without significant side effects during the treatment course. They all exhibited increased muscle power, with considerable improvement in cardiac function. Pompe disease is heterogeneous regarding both clinical features and molecular characteristics. Early identification of Pompe disease is very important, considering that enzyme replacement therapy is a safe and effective treatment for early-onset patients.
Muscle & Nerve | 2017
Anna Cho; Moon Woo Seong; Byung Chan Lim; Hwa Jeen Lee; Jung Hye Byeon; Seung Soo Kim; Soo Yeon Kim; Sun Ah Choi; Ai Lynn Wong; Jeongho Lee; Jon Soo Kim; Hye Won Ryu; Jin Sook Lee; Hunmin Kim; Hee Hwang; Ji Eun Choi; Ki Joong Kim; Young Seung Hwang; Ki Ho Hong; Seungman Park; Sung Im Cho; Seung Jun Lee; Hyunwoong Park; Soo Hyun Seo; Sung Sup Park; Jong Hee Chae
Duchenne and Becker muscular dystrophies (DMD and BMD) are allelic X‐linked recessive muscle diseases caused by mutations in the large and complex dystrophin gene.
Archive | 2013
Anna Cho; Satoru Noguchi
Muscle diseases represent specific muscle pathology. The characteristic features as hallmarks of diseases have been historically used to diagnose the patients. The “Rimmed vacuole (RV)” (Figures 1) is one of such characteristic features in certain groups of the diseases. This structure consists of the space (vacuole) and purple granules (rim) within myofibers, while the space is sometimes occupied with cytosolic contents indicating that the space is artificially produced during the staining process and the rims have the nature of this pathological hallmark. Ultrastructurally, as discussed later, many autophagic vacuoles and multi-lamellar bodies are observed in RVs.
Brain | 2014
Takahiro Yonekawa; May Christine V. Malicdan; Anna Cho; Yukiko K. Hayashi; Ikuya Nonaka; Toshiki Mine; Takeshi Yamamoto; Ichizo Nishino; S. Noguchi
Journal of Neuro-oncology | 2012
Ji Hoon Phi; Seung-Ki Kim; Anna Cho; Dong Gyu Kim; Sun Ha Paek; Sung-Hye Park; Kyu-Chang Wang
Childs Nervous System | 2014
Anna Cho; Jong-Hee Chae; Hun Min Kim; Byung Chan Lim; Hee Hwang; Yong Seung Hwang; Ji Hoon Phi; Seung-Ki Kim; Kyu-Chang Wang; Byung-Kyu Cho; Ki Joong Kim